Nabla Bio, a Boston, MA-based next-generation antibody design company, announced the closing of an $11 million seed financing round.
The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others.
The new funding will be used to accelerate the development of an AI-first protein design platform, enabling rapid end-to-end engineering of next-generation antibody therapeutics.
Company: Nabla Bio, Inc.
Round: Seed Round
Funding Month: December 2021
Lead Investors: Khosla Ventures and Zetta Venture Partners
Additional Investors: Fifty Years, and Cantos Ventures
Company Website: https://www.nabla.bio/
Software Category: AI-first protein design platform
About the Company: Nabla Bio is an antibody design company. The company’s AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design. The company has a fully functional wet lab to complement its machine learning capabilities. Nabla Bio is based in Boston, MA.